Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.34 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891770 | 0.89 | PKM (0.46) | SLC6A2SLC6A4SLC6A3PKMALDH1A1 | |
| SCHEMBL9891759 | 0.89 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL9891766 | 0.85 | IDO1 (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9891773 | 0.83 | HDAC1 (0.36) | CCR1CCR2MDM2 | |
| SCHEMBL9891760 | 0.82 | KMT2A (0.45) | SLC6A2SLC6A4SLC6A3BRD9ALDH1A1 | |
| SCHEMBL16480426 | 0.81 | SLC6A2 (0.53) | CCR1CCR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9891731 | 0.81 | CNR2 (0.42) | CCR1CCR2CNR2ALDH1A1NOTUM | |
| SCHEMBL9891763 | 0.81 | CCR1 (0.43) | CCR1CCR2ALDH1A1TP53 | |
| SCHEMBL9891757 | 0.80 | MDM2 (0.47) | CCR1CCR2ALDH1A1NOTUMTP53 | |
| SCHEMBL9891751 | 0.79 | GAA (0.42) | CCR1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CCR1 158/4885CCR2 6/4885SLC6A2 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.